Ferrous Sulphate + Folic Acid Tablets remain one of the most widely used pharmaceutical combinations for the treatment and prevention of iron deficiency anemia, a condition that affects millions globally. As a trusted formulation across healthcare systems, these tablets provide essential iron supplementation along with folic acid, supporting red blood cell production, hemoglobin regeneration, and overall hematological health.

This comprehensive technical article provides an in-depth overview of specifications, formulation characteristics, regulatory compliance standards, packaging formats, therapeutic indications, and storage conditions. With a commitment to scientific accuracy and industry relevance, this guide serves as a complete reference for healthcare professionals, procurement teams, regulatory bodies, and pharmaceutical distributors.

Product Identity and Technical Composition

Product Overview

Product Name: Ferrous Sulphate + Folic Acid Tablets
Brand Name: Generic
Dosage Form: Un-coated Tablets
Route of Administration: Oral
Therapeutic Category: Blood Products
Packaging: 10s, 20s, 30s, 50s, 150s
Regulatory Documentation: COA, MOA, COPP, FSC, GMP, Stability Studies, CTD Dossier
Pack Information: Includes PIL (Patient Information Leaflet) and SmPC (Summary of Product Characteristics)

This formulation is available in three core strengths, designed to meet varying clinical requirements for anemia management:

0.35mg + 80mg
2.5mg + 300mg
0.5mg + 200mg

These combinations are optimized to deliver bioavailable iron while ensuring sufficient folic acid levels to support erythropoiesis.

Detailed Composition and Strength Variants

Ferrous Sulphate + Folic Acid Tablet (80mg + 0.35mg)

Each un-coated tablet contains:

Dried Iron Ferrous Sulphate USP – 80mg
Folic Acid USP – 0.35mg

This low-to-moderate strength is suitable for routine supplementation and mild to moderate iron deficiency.

Ferrous Sulphate + Folic Acid Tablet (300mg + 2.5mg)

Each un-coated tablet contains:

Dried Iron Ferrous Sulphate USP – 300mg
Folic Acid USP – 2.5mg

This high-strength formulation is recommended for severe iron deficiency anemia or for therapeutic use under strict medical supervision.

Ferrous Sulphate + Folic Acid Tablet (200mg + 0.5mg)

Each un-coated tablet contains:

Dried Iron Ferrous Sulphate USP – 200mg
Folic Acid USP – 0.5mg

Ideal for moderate-to-severe anemia and in populations requiring increased folic acid levels, such as pregnant women or those with chronic nutritional deficiencies.

Pharmaceutical Characteristics and Quality Standards

API Quality and Compliance

The formulation is manufactured using USP-grade Active Pharmaceutical Ingredients, ensuring pharmaceutical purity, stability, and therapeutic efficacy.

Dried Ferrous Sulphate USP

This iron source is widely valued for its high bioavailability, predictable absorption profile, and efficacy in restoring depleted iron stores.

Folic Acid USP

A critical B-vitamin essential for DNA synthesis and cell division, folic acid supports the production of healthy red blood cells, preventing folate-related anemia.

Both ingredients conform to globally recognized pharmacopeial standards, ensuring consistency across batches and guaranteeing patient safety.

Therapeutic Use and Indications

Primary Indications

Ferrous Sulphate + Folic Acid Tablets are clinically indicated for:

Iron deficiency anemia
Folate deficiency anemia
Nutritional anemia due to inadequate dietary intake
Pregnancy-related anemia
Post-surgical or chronic blood loss anemia
Supplementation in chronic illnesses requiring higher hematological support

The combined formulation corrects low iron stores, improves hemoglobin levels, and supports rapid regeneration of red blood cells.

Mechanism of Action

Iron Replenishment

Ferrous sulfate provides elemental iron, which is an essential component of hemoglobin and myoglobin. It plays a vital role in:

Oxygen transport
Cellular respiration
Enzyme function
Energy metabolism

Folic Acid Support

Folic acid supports:

DNA synthesis
Maturation of red blood cells
Prevention of neural tube defects in pregnancy

The synergy of these two nutrients ensures enhanced hematopoietic function, making the formulation a staple in global anemia management.

Regulatory Compliance and Documentation

To meet international marketing and regulatory requirements, the product is supported with:

Certificate of Analysis (COA)
Method of Analysis (MOA)
Certificate of Pharmaceutical Product (COPP)
Free Sale Certificate (FSC)
Good Manufacturing Practice (GMP) Certification
Stability Studies (Accelerated & Long-Term)
CTD Dossier (Module 1–5)

This ensures complete transparency, quality assurance, and compliance with national and international regulatory frameworks.

Packaging and Patient Information

Packaging Options

Available in 10s, 20s, 30s, 50s, and 150s blister or bottle formats, offering flexibility for hospitals, clinics, and distributors.

Pack Insert and Leaflet

Each pack includes:

Patient Information Leaflet (PIL)
SmPC, detailing clinical pharmacology, contraindications, interactions, and dosing guidelines

Caution and Safety Warnings

Read the enclosed leaflet before use.
Keep medicine out of reach of children.
Swallow the tablet whole – DO NOT chew or crush.
To be sold by retail on the prescription of a Registered Medical Practitioner only.

These warnings help ensure safe administration, prevent accidental overdose, and comply with global regulatory standards.

Dosage and Administration

Dosage: As directed by the Physician
Route: Oral
Use: Attach dispensing label as per jurisdictional requirements.

Because iron requirements vary based on age, health condition, severity of anemia, and physiological state (e.g., pregnancy), dosage adjustments must only be done by medical professionals.

Storage Conditions

For optimal stability and preservation of therapeutic potency:

Store at 20° to 25°C (68° to 77°F)
Keep in a dry place away from direct sunlight
Protect from excessive heat and moisture

Proper storage ensures the tablet retains its pharmacological integrity throughout its shelf life.

Why Ferrous Sulphate + Folic Acid Tablets Are Clinically Preferred

This formulation remains a first-line therapy due to:

High iron bioavailability
Affordable and widely accessible
Suitable for multiple anemia types
Proven clinical safety
Compatibility with prenatal and postnatal care
Support for rapid red cell formation

Healthcare systems trust this combination for efficient anemia correction, enhanced patient compliance, and long-term nutritional support.

Ferrous Sulphate + Folic Acid Tablets remain an indispensable therapeutic solution for managing anemia across diverse patient populations. With robust pharmaceutical standards, multiple dosage strengths, extensive regulatory documentation, and proven clinical benefits, this formulation continues to play a crucial role in global healthcare. Its reliability, safety profile, and therapeutic precision make it an essential component of anemia management protocols worldwide.